(1)
OTTAWA, ON / ACCESSWIRE / December 29, 2020 / Innovative Medicines Canada (IMC) issued the following statement today regarding the looming implementation of the Patented Medicines Prices Review Board's (PMPRB's) Final Regulations and Guidelines on January 1, 2021.
"While COVID-19 vaccines from several innovative pharmaceutical companies have provided Canadians a glimmer of hope, the pandemic is far from over. Throughout, we have seen just how important the life sciences sector is to Canadians' health and well-being. Unfortunately, if the federal government proceeds with the implementation, on January 01, 2021, of the amended PMPRB Regulations and Guidelines, Canadians' access to potentially life-saving new medicines and vaccines will be limited.
"In fact, we are already seeing the negative impact of the changes, even before they come into force. New drugs are not being launched in Canada, clinical trials have declined, and investments in our vital life sciences sector are being scaled back. While January 1 is just days away, there is still time for the federal government to act.